Sarepta and Biomarin resolve patent dispute with $35m licence

20-07-2017

Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.


Sarepta Therapeutics, Biomarin Pharmaceutical, licence agreement, patent, settlement, muscular dystrophy

LSIPR